{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:45:32Z","timestamp":1794012332998,"version":"4.8.0"},"reference-count":176,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41584-026-01388-0","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:59:06Z","timestamp":1781863146000},"page":"479-495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["TLR7 in systemic lupus erythematosus: genetics and emerging therapies"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9799-0298","authenticated-orcid":false,"given":"Carola G.","family":"Vinuesa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhumita","family":"Shrotri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2346-4484","authenticated-orcid":false,"given":"Anisur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"1388_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/annrheumdis-2014-206334","volume":"75","author":"F Rees","year":"2016","unstructured":"Rees, F. et al. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann. Rheum. Dis. 75, 136\u2013141 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1388_CR2","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","volume":"331","author":"CH Siegel","year":"2024","unstructured":"Siegel, C. H. & Sammaritano, L. R. Systemic lupus erythematosus: a review. JAMA 331, 1480\u20131491 (2024).","journal-title":"JAMA"},{"key":"1388_CR3","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1126\/science.adg6427","volume":"380","author":"CG Vinuesa","year":"2023","unstructured":"Vinuesa, C. G., Grenov, A. & Kassiotis, G. Innate virus-sensing pathways in B cell systemic autoimmunity. Science 380, 478\u2013484 (2023).","journal-title":"Science"},{"key":"1388_CR4","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1172\/JCI114831","volume":"86","author":"DM Klinman","year":"1990","unstructured":"Klinman, D. M. Polyclonal B cell activation in lupus-prone mice precedes and predicts the development of autoimmune disease. J. Clin. Invest. 86, 1249\u20131254 (1990).","journal-title":"J. Clin. Invest."},{"key":"1388_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/sj.ki.5002133","volume":"71","author":"M Kalaaji","year":"2007","unstructured":"Kalaaji, M. et al. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int. 71, 664\u2013672 (2007).","journal-title":"Kidney Int."},{"key":"1388_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","volume":"49","author":"SA Jenks","year":"2018","unstructured":"Jenks, S. A. et al. Distinct effector B cells induced by unregulated Toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity 49, 725\u2013739.e6 (2018).","journal-title":"Immunity"},{"key":"1388_CR7","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41581-023-00732-x","volume":"19","author":"CG Vinuesa","year":"2023","unstructured":"Vinuesa, C. G., Shen, N. & Ware, T. Genetics of SLE: mechanistic insights from monogenic disease and disease-associated variants. Nat. Rev. Nephrol. 19, 558\u2013572 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"1388_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41586-022-04642-z","volume":"605","author":"GJ Brown","year":"2022","unstructured":"Brown, G. J. et al. TLR7 gain-of-function genetic variation causes human lupus. Nature 605, 349\u2013356 (2022).","journal-title":"Nature"},{"key":"1388_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-024-01824-4","volume":"45","author":"S Menon","year":"2024","unstructured":"Menon, S. et al. Refractory autoimmune thrombocytopenia in an infant with a de novo TLR7 gain-of-function variant. J. Clin. Immunol. 45, 27 (2024).","journal-title":"J. Clin. Immunol."},{"key":"1388_CR10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232066","volume":"221","author":"C David","year":"2024","unstructured":"David, C. et al. Gain-of-function human UNC93B1 variants cause systemic lupus erythematosus and chilblain lupus. J. Exp. Med. 221, e20232066 (2024).","journal-title":"J. Exp. Med."},{"key":"1388_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-024-01660-6","volume":"44","author":"C David","year":"2024","unstructured":"David, C. et al. Interface gain-of-function mutations in TLR7 cause systemic and neuro-inflammatory disease. J. Clin. Immunol. 44, 60 (2024).","journal-title":"J. Clin. Immunol."},{"key":"1388_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi9575","volume":"9","author":"H Mishra","year":"2024","unstructured":"Mishra, H. et al. Disrupted degradative sorting of TLR7 is associated with human lupus. Sci. Immunol. 9, eadi9575 (2024).","journal-title":"Sci. Immunol."},{"key":"1388_CR13","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41590-024-01846-5","volume":"25","author":"M Al-Azab","year":"2024","unstructured":"Al-Azab, M. et al. Genetic variants in UNC93B1 predispose to childhood-onset systemic lupus erythematosus. Nat. Immunol. 25, 969\u2013980 (2024).","journal-title":"Nat. Immunol."},{"key":"1388_CR14","doi-asserted-by":"publisher","unstructured":"Han, X. et al. Immune dysregulation caused by novel gain-of-function UNC93B1 variant with enhanced antigen presentation. Genes Dis. https:\/\/doi.org\/10.1016\/j.gendis.2026.102187 (2026).","DOI":"10.1016\/j.gendis.2026.102187"},{"key":"1388_CR15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179193","volume":"134","author":"J Stremenova Spegarova","year":"2024","unstructured":"Stremenova Spegarova, J. et al. A de novo TLR7 gain-of-function mutation causing severe monogenic lupus in an infant. J. Clin. Invest. 134, e179193 (2024).","journal-title":"J. Clin. Invest."},{"key":"1388_CR16","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250199","volume":"2","author":"M Tusseau","year":"2026","unstructured":"Tusseau, M. et al. Novel TLR7 gain-of-function variant and review of the associated disease spectrum. J. Hum. Immun. 2, e20250199 (2026).","journal-title":"J. Hum. Immun."},{"key":"1388_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi9769","volume":"9","author":"C Wolf","year":"2024","unstructured":"Wolf, C. et al. UNC93B1 variants underlie TLR7-dependent autoimmunity. Sci. Immunol. 9, eadi9769 (2024).","journal-title":"Sci. Immunol."},{"key":"1388_CR18","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ard.2025.01.011","volume":"84","author":"Y Zeng","year":"2025","unstructured":"Zeng, Y. et al. Somatic gain-of-function mutation in TLR7 causes early-onset systemic lupus erythematosus. Ann. Rheum. Dis. 84, 442\u2013450 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1388_CR19","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250196","volume":"2","author":"N Parvaneh","year":"2026","unstructured":"Parvaneh, N. et al. TLR7 F507S gain-of-function mutation presenting with early-onset SLE and hypertriglyceridemia: response to JAK inhibition. J. Hum. Immun. 2, e20250196\u00a0(2026).","journal-title":"J. Hum. Immun."},{"key":"1388_CR20","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250194","volume":"2","author":"A Sethumadhavan","year":"2026","unstructured":"Sethumadhavan, A. et al. Identification of a novel TLR7 gain-of-function variant that underlies systemic lupus erythematosus. J. Hum. Immun. 2, e20250194 (2026).","journal-title":"J. Hum. Immun."},{"key":"1388_CR21","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.1073\/pnas.0400937101","volume":"101","author":"JM Lund","year":"2004","unstructured":"Lund, J. M. et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl Acad. Sci. USA 101, 5598\u20135603 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1388_CR22","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1126\/science.1093616","volume":"303","author":"SS Diebold","year":"2004","unstructured":"Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S. & Reis e Sousa, C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529\u20131531 (2004).","journal-title":"Science"},{"key":"1388_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl4348","volume":"6","author":"T Asano","year":"2021","unstructured":"Asano, T. et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci. Immunol. 6, eabl4348 (2021).","journal-title":"Sci. Immunol."},{"key":"1388_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55692-y","volume":"16","author":"A Drobek","year":"2025","unstructured":"Drobek, A. et al. The TLR7\/9 adaptors TASL and TASL2 mediate IRF5-dependent antiviral responses and autoimmunity in mouse. Nat. Commun. 16, 967 (2025).","journal-title":"Nat. Commun."},{"key":"1388_CR25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41586-020-2282-0","volume":"581","author":"LX Heinz","year":"2020","unstructured":"Heinz, L. X. et al. TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9. Nature 581, 316\u2013322 (2020).","journal-title":"Nature"},{"key":"1388_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55690-0","volume":"16","author":"L Lau","year":"2025","unstructured":"Lau, L. et al. An essential role for TASL in mouse autoimmune pathogenesis and Toll-like receptor signaling. Nat. Commun. 16, 968 (2025).","journal-title":"Nat. Commun."},{"key":"1388_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112916","volume":"42","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. SLC15A4 controls endolysosomal TLR7-9 responses by recruiting the innate immune adaptor TASL. Cell Rep. 42, 112916 (2023).","journal-title":"Cell Rep."},{"key":"1388_CR28","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41590-026-02429-2","volume":"27","author":"AS Alharbi","year":"2026","unstructured":"Alharbi, A. S. et al. 2\u2019-O-Methyl-guanosine RNA fragments antagonize TLR7 and TLR8 to limit autoimmunity. Nat. Immunol. 27, 762\u2013775\u00a0(2026).","journal-title":"Nat. Immunol."},{"key":"1388_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70059","volume":"7","author":"F Hosein","year":"2025","unstructured":"Hosein, F. et al. Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of afimetoran, a Toll-like receptor 7 and 8 inhibitor, in patients with cutaneous lupus erythematosus: a phase 1b randomized, double-blind, placebo-controlled study. ACR Open. Rheumatol. 7, e70059 (2025).","journal-title":"ACR Open. Rheumatol."},{"key":"1388_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.6117","author":"G Senaldi","year":"2024","unstructured":"Senaldi, G. et al. First-in-human study of the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of DS-7011a, an anti-TLR7 antagonistic monoclonal antibody for the treatment of systemic lupus erythematosus. J. Clin. Pharmacol. https:\/\/doi.org\/10.1002\/jcph.6117 (2024).","journal-title":"J. Clin. Pharmacol."},{"key":"1388_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.842","volume":"9","author":"A Port","year":"2021","unstructured":"Port, A. et al. Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8. Pharmacol. Res. Perspect. 9, e00842 (2021).","journal-title":"Pharmacol. Res. Perspect."},{"key":"1388_CR32","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1089\/jir.2012.0014","volume":"32","author":"ST Sarvestani","year":"2012","unstructured":"Sarvestani, S. T., Williams, B. R. & Gantier, M. P. Human Toll-like receptor 8 can be cool too: implications for foreign RNA sensing. J. Interferon Cytokine Res. 32, 350\u2013361 (2012).","journal-title":"J. Interferon Cytokine Res."},{"key":"1388_CR33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41594-020-00542-w","volume":"28","author":"H Ishida","year":"2021","unstructured":"Ishida, H. et al. Cryo-EM structures of Toll-like receptors in complex with UNC93B1. Nat. Struct. Mol. Biol. 28, 173\u2013180 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1388_CR34","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.immuni.2016.09.011","volume":"45","author":"Z Zhang","year":"2016","unstructured":"Zhang, Z. et al. Structural analysis reveals that Toll-like receptor 7 is a dual receptor for guanosine and single-stranded RNA. Immunity 45, 737\u2013748 (2016).","journal-title":"Immunity"},{"key":"1388_CR35","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1016\/j.celrep.2018.11.081","volume":"25","author":"Z Zhang","year":"2018","unstructured":"Zhang, Z. et al. Structural analyses of Toll-like receptor 7 reveal detailed RNA sequence specificity and recognition mechanism of agonistic ligands. Cell Rep. 25, 3371\u20133381.e3375 (2018).","journal-title":"Cell Rep."},{"key":"1388_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nsmb.2943","volume":"22","author":"H Tanji","year":"2015","unstructured":"Tanji, H. et al. Toll-like receptor 8 senses degradation products of single-stranded RNA. Nat. Struct. Mol. Biol. 22, 109\u2013115 (2015).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1388_CR37","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1126\/science.1229159","volume":"339","author":"H Tanji","year":"2013","unstructured":"Tanji, H., Ohto, U., Shibata, T., Miyake, K. & Shimizu, T. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands. Science 339, 1426\u20131429 (2013).","journal-title":"Science"},{"key":"1388_CR38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/intimm\/dxv062","volume":"28","author":"T Shibata","year":"2016","unstructured":"Shibata, T. et al. Guanosine and its modified derivatives are endogenous ligands for TLR7. Int. Immunol. 28, 211\u2013222 (2016).","journal-title":"Int. Immunol."},{"key":"1388_CR39","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1126\/science.1093620","volume":"303","author":"F Heil","year":"2004","unstructured":"Heil, F. et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303, 1526\u20131529 (2004).","journal-title":"Science"},{"key":"1388_CR40","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm1191","volume":"11","author":"V Hornung","year":"2005","unstructured":"Hornung, V. et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263\u2013270 (2005).","journal-title":"Nat. Med."},{"key":"1388_CR41","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.131093","volume":"5","author":"P Dembny","year":"2020","unstructured":"Dembny, P. et al. Human endogenous retrovirus HERV-K(HML-2) RNA causes neurodegeneration through Toll-like receptors. JCI Insight 5, e131093 (2020).","journal-title":"JCI Insight"},{"key":"1388_CR42","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191766","volume":"218","author":"M Tokuyama","year":"2021","unstructured":"Tokuyama, M. et al. Antibodies against human endogenous retrovirus K102 envelope activate neutrophils in systemic lupus erythematosus. J. Exp. Med. 218, e20191766 (2021).","journal-title":"J. Exp. Med."},{"key":"1388_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147705","volume":"25","author":"RS Mahla","year":"2024","unstructured":"Mahla, R. S., Jones, E. L. & Dustin, L. B. Ro60\u2014Roles in RNA processing, inflammation, and rheumatic autoimmune diseases. Int. J. Mol. Sci. 25, 7705 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1388_CR44","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.169344","volume":"8","author":"JD Crawford","year":"2023","unstructured":"Crawford, J. D. et al. The XIST lncRNA is a sex-specific reservoir of TLR7 ligands in SLE. JCI Insight 8, e169344 (2023).","journal-title":"JCI Insight"},{"key":"1388_CR45","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/intimm\/dxab033","volume":"33","author":"K Liu","year":"2021","unstructured":"Liu, K. et al. Skewed endosomal RNA responses from TLR7 to TLR3 in RNase T2-deficient macrophages. Int. Immunol. 33, 479\u2013490 (2021).","journal-title":"Int. Immunol."},{"key":"1388_CR46","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.immuni.2024.04.010","volume":"57","author":"M Berouti","year":"2024","unstructured":"Berouti, M. et al. Lysosomal endonuclease RNase T2 and PLD exonucleases cooperatively generate RNA ligands for TLR7 activation. Immunity 57, 1482\u20131496.e8 (2024).","journal-title":"Immunity"},{"key":"1388_CR47","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.cell.2019.11.001","volume":"179","author":"W Greulich","year":"2019","unstructured":"Greulich, W. et al. TLR8 is a sensor of RNase T2 degradation products. Cell 179, 1264\u20131275.e13 (2019).","journal-title":"Cell"},{"key":"1388_CR48","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.immuni.2020.03.009","volume":"52","author":"T Ostendorf","year":"2020","unstructured":"Ostendorf, T. et al. Immune sensing of synthetic, bacterial, and protozoan RNA by Toll-like receptor 8 requires coordinated processing by RNase T2 and RNase 2. Immunity 52, 591\u2013605.e6 (2020).","journal-title":"Immunity"},{"key":"1388_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26150-w","volume":"12","author":"AL Gavin","year":"2021","unstructured":"Gavin, A. L. et al. Cleavage of DNA and RNA by PLD3 and PLD4 limits autoinflammatory triggering by multiple sensors. Nat. Commun. 12, 5874 (2021).","journal-title":"Nat. Commun."},{"key":"1388_CR50","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41590-018-0179-y","volume":"19","author":"AL Gavin","year":"2018","unstructured":"Gavin, A. L. et al. PLD3 and PLD4 are single-stranded acid exonucleases that regulate endosomal nucleic-acid sensing. Nat. Immunol. 19, 942\u2013953 (2018).","journal-title":"Nat. Immunol."},{"key":"1388_CR51","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Kariko","year":"2005","unstructured":"Kariko, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165\u2013175 (2005).","journal-title":"Immunity"},{"key":"1388_CR52","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41577-021-00577-0","volume":"22","author":"NA Lind","year":"2022","unstructured":"Lind, N. A., Rael, V. E., Pestal, K., Liu, B. & Barton, G. M. Regulation of the nucleic acid-sensing Toll-like receptors. Nat. Rev. Immunol. 22, 224\u2013235 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1388_CR53","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3899\/jrheum.2025-0390.PV063","volume":"52","author":"O Laczka","year":"2025","unstructured":"Laczka, O. et al. Novel 3-base oligonucleotide therapeutic SOF-SKN\u2122 antagonises TLR7\/8 in autoimmune skin disease. J. Rheumatol. 52, 116\u2013116 (2025).","journal-title":"J. Rheumatol."},{"key":"1388_CR54","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.immuni.2006.07.013","volume":"25","author":"SR Christensen","year":"2006","unstructured":"Christensen, S. R. et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417\u2013428 (2006).","journal-title":"Immunity"},{"key":"1388_CR55","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1126\/science.1124978","volume":"312","author":"P Pisitkun","year":"2006","unstructured":"Pisitkun, P. et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312, 1669\u20131672 (2006).","journal-title":"Science"},{"key":"1388_CR56","doi-asserted-by":"publisher","first-page":"9970","DOI":"10.1073\/pnas.0603912103","volume":"103","author":"S Subramanian","year":"2006","unstructured":"Subramanian, S. et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc. Natl Acad. Sci. USA 103, 9970\u20139975 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1388_CR57","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1136\/ard.2009.124313","volume":"69","author":"H Garcia-Ortiz","year":"2010","unstructured":"Garcia-Ortiz, H. et al. Association of TLR7 copy number variation with susceptibility to childhood-onset systemic lupus erythematosus in Mexican population. Ann. Rheum. Dis. 69, 1861\u20131865 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1388_CR58","doi-asserted-by":"publisher","first-page":"15838","DOI":"10.1073\/pnas.1001337107","volume":"107","author":"N Shen","year":"2010","unstructured":"Shen, N. et al. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 107, 15838\u201315843 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1388_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/ar3277","volume":"13","author":"A Kawasaki","year":"2011","unstructured":"Kawasaki, A. et al. TLR7 single-nucleotide polymorphisms in the 3\u2019 untranslated region and intron 2 independently contribute to systemic lupus erythematosus in Japanese women: a case-control association study. Arthritis Res. Ther. 13, R41 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"1388_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aap8855","volume":"3","author":"M Souyris","year":"2018","unstructured":"Souyris, M. et al. TLR7 escapes X chromosome inactivation in immune cells. Sci. Immunol. 3, eaap8855 (2018).","journal-title":"Sci. Immunol."},{"key":"1388_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1479814","volume":"16","author":"RH Scofield","year":"2025","unstructured":"Scofield, R. H., Wren, J. D. & Lewis, V. M. The Toll like receptor 7 pathway and the sex bias of systemic lupus erythematosus. Front. Immunol. 16, 1479814 (2025).","journal-title":"Front. Immunol."},{"key":"1388_CR62","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.cell.2023.12.037","volume":"187","author":"DR Dou","year":"2024","unstructured":"Dou, D. R. et al. Xist ribonucleoproteins promote female sex-biased autoimmunity. Cell 187, 733\u2013749.e16 (2024).","journal-title":"Cell"},{"key":"1388_CR63","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.4049\/jimmunol.0803899","volume":"183","author":"NM Green","year":"2009","unstructured":"Green, N. M. et al. Murine B cell response to TLR7 ligands depends on an IFN-\u03b2 feedback loop. J. Immunol. 183, 1569\u20131576 (2009).","journal-title":"J. Immunol."},{"key":"1388_CR64","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1189\/jlb.0212064","volume":"92","author":"S Sinha","year":"2012","unstructured":"Sinha, S., Guo, Y., Thet, S. & Yuan, D. IFN type I and type II independent enhancement of B cell TLR7 expression by natural killer cells. J. Leukoc. Biol. 92, 713\u2013722 (2012).","journal-title":"J. Leukoc. Biol."},{"key":"1388_CR65","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/s41590-020-0743-0","volume":"21","author":"D Nehar-Belaid","year":"2020","unstructured":"Nehar-Belaid, D. et al. Mapping systemic lupus erythematosus heterogeneity at the single-cell level. Nat. Immunol. 21, 1094\u20131106 (2020).","journal-title":"Nat. Immunol."},{"key":"1388_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03311-y","volume":"26","author":"S Wei","year":"2024","unstructured":"Wei, S. et al. Integrative analysis of single-cell and bulk transcriptome data reveal the significant role of macrophages in lupus nephritis. Arthritis Res. Ther. 26, 84 (2024).","journal-title":"Arthritis Res. Ther."},{"key":"1388_CR67","doi-asserted-by":"publisher","first-page":"15160","DOI":"10.1073\/pnas.2000943117","volume":"117","author":"C Jing","year":"2020","unstructured":"Jing, C. et al. Macrophage metabolic reprogramming presents a therapeutic target in lupus nephritis. Proc. Natl Acad. Sci. USA 117, 15160\u201315171 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1388_CR68","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1146\/annurev-immunol-101921-042422","volume":"41","author":"S Caielli","year":"2023","unstructured":"Caielli, S., Wan, Z. & Pascual, V. Systemic lupus erythematosus pathogenesis: interferon and beyond. Annu. Rev. Immunol. 41, 533\u2013560 (2023).","journal-title":"Annu. Rev. Immunol."},{"key":"1388_CR69","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41590-024-01898-7","volume":"25","author":"GC Tsokos","year":"2024","unstructured":"Tsokos, G. C. The immunology of systemic lupus erythematosus. Nat. Immunol. 25, 1332\u20131343 (2024).","journal-title":"Nat. Immunol."},{"key":"1388_CR70","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.immuni.2006.08.010","volume":"25","author":"J Banchereau","year":"2006","unstructured":"Banchereau, J. & Pascual, V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25, 383\u2013392 (2006).","journal-title":"Immunity"},{"key":"1388_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222011286","volume":"22","author":"M Ramaswamy","year":"2021","unstructured":"Ramaswamy, M., Tummala, R., Streicher, K., Nogueira da Costa, A. & Brohawn, P. Z. The pathogenesis, molecular mechanisms, and therapeutic potential of the interferon pathway in systemic lupus erythematosus and other autoimmune diseases. Int. J. Mol. Sci. 22, 11286 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1388_CR72","first-page":"1662","volume":"56","author":"A Psarras","year":"2017","unstructured":"Psarras, A., Emery, P. & Vital, E. M. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology 56, 1662\u20131675 (2017).","journal-title":"Rheumatology"},{"key":"1388_CR73","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4049\/immunohorizons.2000002","volume":"4","author":"AT Bender","year":"2020","unstructured":"Bender, A. T. et al. TLR7 and TLR8 differentially activate the IRF and NF-\u03baB pathways in specific cell types to promote inflammation. Immunohorizons 4, 93\u2013107 (2020).","journal-title":"Immunohorizons"},{"key":"1388_CR74","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1084\/jem.20161512","volume":"214","author":"C Lood","year":"2017","unstructured":"Lood, C., Arve, S., Ledbetter, J. & Elkon, K. B. TLR7\/8 activation in neutrophils impairs immune complex phagocytosis through shedding of FcgRIIA. J. Exp. Med. 214, 2103\u20132119 (2017).","journal-title":"J. Exp. Med."},{"key":"1388_CR75","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1189\/jlb.2A1214-623R","volume":"97","author":"K Makni-Maalej","year":"2015","unstructured":"Makni-Maalej, K. et al. TLR8, but not TLR7, induces the priming of the NADPH oxidase activation in human neutrophils. J. Leukoc. Biol. 97, 1081\u20131087 (2015).","journal-title":"J. Leukoc. Biol."},{"key":"1388_CR76","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller, F. et al. CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1388_CR77","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1084\/jem.20122798","volume":"210","author":"NV Giltiay","year":"2013","unstructured":"Giltiay, N. V. et al. Overexpression of TLR7 promotes cell-intrinsic expansion and autoantibody production by transitional T1 B cells. J. Exp. Med. 210, 2773\u20132789 (2013).","journal-title":"J. Exp. Med."},{"key":"1388_CR78","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41584-020-00544-4","volume":"17","author":"S Fillatreau","year":"2021","unstructured":"Fillatreau, S., Manfroi, B. & Dorner, T. Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nat. Rev. Rheumatol. 17, 98\u2013108 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1388_CR79","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/aps.2015.91","volume":"36","author":"YW Wu","year":"2015","unstructured":"Wu, Y. W., Tang, W. & Zuo, J. P. Toll-like receptors: potential targets for lupus treatment. Acta Pharmacol. Sin. 36, 1395\u20131407 (2015).","journal-title":"Acta Pharmacol. Sin."},{"key":"1388_CR80","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adj4748","volume":"9","author":"X Gao","year":"2024","unstructured":"Gao, X. et al. Zeb2 drives the formation of CD11c+ atypical B cells to sustain germinal centers that control persistent infection. Sci. Immunol. 9, eadj4748 (2024).","journal-title":"Sci. Immunol."},{"key":"1388_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166322","volume":"11","author":"K Rubtsova","year":"2016","unstructured":"Rubtsova, K. et al. T cell production of IFN\u03b3 in response to TLR7\/IL-12 stimulates optimal B cell responses to viruses. PLoS ONE 11, e0166322 (2016).","journal-title":"PLoS ONE"},{"key":"1388_CR82","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/ni.3036","volume":"16","author":"M Dominguez-Villar","year":"2015","unstructured":"Dominguez-Villar, M., Gautron, A. S., de Marcken, M., Keller, M. J. & Hafler, D. A. TLR7 induces anergy in human CD4+ T cells. Nat. Immunol. 16, 118\u2013128 (2015).","journal-title":"Nat. Immunol."},{"key":"1388_CR83","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.4049\/jimmunol.175.3.1551","volume":"175","author":"G Caron","year":"2005","unstructured":"Caron, G. et al. Direct stimulation of human T cells via TLR5 and TLR7\/8: flagellin and R-848 up-regulate proliferation and IFN-\u03b3 production by memory CD4+ T cells. J. Immunol. 175, 1551\u20131557 (2005).","journal-title":"J. Immunol."},{"key":"1388_CR84","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/s41590-022-01310-2","volume":"23","author":"C Leibler","year":"2022","unstructured":"Leibler, C. et al. Genetic dissection of TLR9 reveals complex regulatory and cryptic proinflammatory roles in mouse lupus. Nat. Immunol. 23, 1457\u20131469 (2022).","journal-title":"Nat. Immunol."},{"key":"1388_CR85","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.172219","volume":"8","author":"HA Cosgrove","year":"2023","unstructured":"Cosgrove, H. A. et al. B cell-intrinsic TLR7 expression drives severe lupus in TLR9-deficient mice. JCI Insight 8, e172219 (2023).","journal-title":"JCI Insight"},{"key":"1388_CR86","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.immuni.2011.05.010","volume":"35","author":"R Fukui","year":"2011","unstructured":"Fukui, R. et al. Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking. Immunity 35, 69\u201381 (2011).","journal-title":"Immunity"},{"key":"1388_CR87","doi-asserted-by":"publisher","first-page":"577","DOI":"10.4049\/immunohorizons.2300058","volume":"7","author":"AL Gavin","year":"2023","unstructured":"Gavin, A. L. et al. Disease in the Pld4thss\/thss model of murine lupus requires TLR9. Immunohorizons 7, 577\u2013586 (2023).","journal-title":"Immunohorizons"},{"key":"1388_CR88","doi-asserted-by":"publisher","DOI":"10.1172\/JCI189566","volume":"35","author":"C Leibler","year":"2025","unstructured":"Leibler, C. et al. Divergent TIR signaling domains in TLR7 and TLR9 control opposing effects on systemic autoimmunity. J. Clin. Invest. 35, e189566\u00a0(2025).","journal-title":"J. Clin. Invest."},{"key":"1388_CR89","volume":"135","author":"R Tach\u00f3-Pi\u00f1ot","year":"2025","unstructured":"Tach\u00f3-Pi\u00f1ot, R. & Vinuesa, C. G. S-TIR-ring up TLR7 and TLR9: signaling domain substitutions clarify the TLR paradox. JCI Insight 135, e198981 (2025).","journal-title":"JCI Insight"},{"key":"1388_CR90","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/bs.ai.2024.02.002","volume":"162","author":"Y He","year":"2024","unstructured":"He, Y. & Vinuesa, C. G. Germinal center versus extrafollicular responses in systemic autoimmunity: who turns the blade on self? Adv. Immunol. 162, 109\u2013133 (2024).","journal-title":"Adv. Immunol."},{"key":"1388_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/flupu.2024.1398035","volume":"2","author":"V Laurynenka","year":"2024","unstructured":"Laurynenka, V. & Harley, J. B. The 330 risk loci known for systemic lupus erythematosus (SLE): a review. Front. Lupus 2, 1398035 (2024).","journal-title":"Front. Lupus"},{"key":"1388_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10242-9","volume":"10","author":"SH Jiang","year":"2019","unstructured":"Jiang, S. H. et al. Functional rare and low frequency variants in BLK and BANK1 contribute to human lupus. Nat. Commun. 10, 2201 (2019).","journal-title":"Nat. Commun."},{"key":"1388_CR93","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/s41590-019-0490-2","volume":"20","author":"TA Schwickert","year":"2019","unstructured":"Schwickert, T. A. et al. Ikaros prevents autoimmunity by controlling anergy and Toll-like receptor signaling in B cells. Nat. Immunol. 20, 1517\u20131529 (2019).","journal-title":"Nat. Immunol."},{"key":"1388_CR94","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.4049\/jimmunol.1600788","volume":"197","author":"SK Nanda","year":"2016","unstructured":"Nanda, S. K., Lopez-Pelaez, M., Arthur, J. S., Marchesi, F. & Cohen, P. Suppression of IRAK1 or IRAK4 catalytic activity, but not type 1 IFN signaling, prevents lupus nephritis in mice expressing a ubiquitin binding-defective mutant of ABIN1. J. Immunol. 197, 4266\u20134273 (2016).","journal-title":"J. Immunol."},{"key":"1388_CR95","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41586-025-09513-x","volume":"647","author":"Q Wang","year":"2025","unstructured":"Wang, Q. et al. Loss-of-function mutations in PLD4 lead to systemic lupus erythematosus. Nature 647, 498\u2013505\u00a0(2025).","journal-title":"Nature"},{"key":"1388_CR96","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-024-05234-y","volume":"81","author":"I Bodega-Mayor","year":"2024","unstructured":"Bodega-Mayor, I. et al. Tyrosine kinase 2 modulates splenic B cells through type I IFN and TLR7 signaling. Cell Mol. Life Sci. 81, 199 (2024).","journal-title":"Cell Mol. Life Sci."},{"key":"1388_CR97","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1073\/pnas.93.4.1624","volume":"93","author":"L Casciola-Rosen","year":"1996","unstructured":"Casciola-Rosen, L., Rosen, A., Petri, M. & Schlissel, M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 93, 1624\u20131629 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1388_CR98","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/BOR.0000000000001008","volume":"36","author":"Y Qin","year":"2024","unstructured":"Qin, Y., Ma, J. & Vinuesa, C. G. Monogenic lupus: insights into disease pathogenesis and therapeutic opportunities. Curr. Opin. Rheumatol. 36, 191\u2013200 (2024).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1388_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102979","volume":"137","author":"SL Coss","year":"2023","unstructured":"Coss, S. L. et al. The complement system and human autoimmune diseases. J. Autoimmun. 137, 102979 (2023).","journal-title":"J. Autoimmun."},{"key":"1388_CR100","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/jth.12796","volume":"13","author":"M Jimenez-Alcazar","year":"2015","unstructured":"Jimenez-Alcazar, M. et al. Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies. J. Thromb. Haemost. 13, 732\u2013742 (2015).","journal-title":"J. Thromb. Haemost."},{"key":"1388_CR101","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/ng.975","volume":"43","author":"SM Al-Mayouf","year":"2011","unstructured":"Al-Mayouf, S. M. et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat. Genet. 43, 1186\u20131188 (2011).","journal-title":"Nat. Genet."},{"key":"1388_CR102","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1177\/09612033241255011","volume":"33","author":"S Sener","year":"2024","unstructured":"Sener, S. et al. Detection of genetic mutations underlying early-onset systemic lupus erythematosus. Lupus 33, 998\u20131003 (2024).","journal-title":"Lupus"},{"key":"1388_CR103","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1007\/s10875-022-01287-5","volume":"42","author":"M Tusseau","year":"2022","unstructured":"Tusseau, M. et al. DNASE1L3 deficiency, new phenotypes, and evidence for a transient type I IFN signaling. J. Clin. Immunol. 42, 1310\u20131320 (2022).","journal-title":"J. Clin. Immunol."},{"key":"1388_CR104","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.immuni.2020.04.015","volume":"52","author":"C Soni","year":"2020","unstructured":"Soni, C. et al. Plasmacytoid dendritic cells and type I interferon promote extrafollicular B cell responses to extracellular self-DNA. Immunity 52, 1022\u20131038.e7 (2020).","journal-title":"Immunity"},{"key":"1388_CR105","doi-asserted-by":"publisher","first-page":"8164","DOI":"10.4049\/jimmunol.177.11.8164","volume":"177","author":"KK Gorden","year":"2006","unstructured":"Gorden, K. K. et al. Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines. J. Immunol. 177, 8164\u20138170 (2006).","journal-title":"J. Immunol."},{"key":"1388_CR106","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/eji.200535806","volume":"36","author":"M Jurk","year":"2006","unstructured":"Jurk, M. et al. Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. Eur. J. Immunol. 36, 1815\u20131826 (2006).","journal-title":"Eur. J. Immunol."},{"key":"1388_CR107","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/91070","volume":"28","author":"K Yasutomo","year":"2001","unstructured":"Yasutomo, K. et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat. Genet. 28, 313\u2013314 (2001).","journal-title":"Nat. Genet."},{"key":"1388_CR108","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aaw1347","volume":"12","author":"M de Marcken","year":"2019","unstructured":"de Marcken, M., Dhaliwal, K., Danielsen, A. C., Gautron, A. S. & Dominguez-Villar, M. TLR7 and TLR8 activate distinct pathways in monocytes during RNA virus infection. Sci. Signal. 12, eaaw1347 (2019).","journal-title":"Sci. Signal."},{"key":"1388_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2024.102482","volume":"91","author":"JA Hamerman","year":"2024","unstructured":"Hamerman, J. A. & Barton, G. M. The path ahead for understanding Toll-like receptor-driven systemic autoimmunity. Curr. Opin. Immunol. 91, 102482 (2024).","journal-title":"Curr. Opin. Immunol."},{"key":"1388_CR110","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1182\/bloodadvances.2025016338","volume":"10","author":"DE Arnold","year":"2025","unstructured":"Arnold, D. E. et al. Clinical characteristics, management, and hematopoietic cell transplantation of patients with TLR8 gain-of-function. Blood Adv. 10, 1967\u20131976\u00a0(2025).","journal-title":"Blood Adv."},{"key":"1388_CR111","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/ajh.26452","volume":"97","author":"M Fejtkova","year":"2022","unstructured":"Fejtkova, M. et al. TLR8\/TLR7 dysregulation due to a novel TLR8 mutation causes severe autoimmune hemolytic anemia and autoinflammation in identical twins. Am. J. Hematol. 97, 338\u2013351 (2022).","journal-title":"Am. J. Hematol."},{"key":"1388_CR112","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1182\/blood.2020009620","volume":"137","author":"J Aluri","year":"2021","unstructured":"Aluri, J. et al. Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of function. Blood 137, 2450\u20132462 (2021).","journal-title":"Blood"},{"key":"1388_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50066-w","volume":"15","author":"J Liang","year":"2024","unstructured":"Liang, J. et al. Erythroid-intrinsic activation of TLR8 impairs erythropoiesis in inherited anemia. Nat. Commun. 15, 5678 (2024).","journal-title":"Nat. Commun."},{"key":"1388_CR114","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41584-024-01192-8","volume":"21","author":"GC Tsokos","year":"2025","unstructured":"Tsokos, G. C. The emergence of SLE-causing UNC93B1 variants in 2024. Nat. Rev. Rheumatol. 21, 67\u201368 (2025).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1388_CR115","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41586-019-1611-7","volume":"575","author":"O Majer","year":"2019","unstructured":"Majer, O. et al. Release from UNC93B1 reinforces the compartmentalized activation of select TLRs. Nature 575, 371\u2013374 (2019).","journal-title":"Nature"},{"key":"1388_CR116","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41586-019-1612-6","volume":"575","author":"O Majer","year":"2019","unstructured":"Majer, O., Liu, B., Kreuk, L. S. M., Krogan, N. & Barton, G. M. UNC93B1 recruits syntenin-1 to dampen TLR7 signalling and prevent autoimmunity. Nature 575, 366\u2013370 (2019).","journal-title":"Nature"},{"key":"1388_CR117","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232005","volume":"221","author":"VE Rael","year":"2024","unstructured":"Rael, V. E. et al. Large-scale mutational analysis identifies UNC93B1 variants that drive TLR-mediated autoimmunity in mice and humans. J. Exp. Med. 221, e20232005 (2024).","journal-title":"J. Exp. Med."},{"key":"1388_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1671984","volume":"16","author":"T He","year":"2025","unstructured":"He, T. et al. Case report: novel UNC93B1 variant causes rheumatoid arthritis and interstitial pneumonia. Front. Immunol. 16, 1671984 (2025).","journal-title":"Front. Immunol."},{"key":"1388_CR119","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.cell.2014.01.019","volume":"156","author":"KS Bonham","year":"2014","unstructured":"Bonham, K. S. et al. A promiscuous lipid-binding protein diversifies the subcellular sites of toll-like receptor signal transduction. Cell 156, 705\u2013716 (2014).","journal-title":"Cell"},{"key":"1388_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21238925","volume":"21","author":"E Leszczynska","year":"2020","unstructured":"Leszczynska, E. et al. Absence of Mal\/TIRAP results in abrogated imidazoquinolinones-dependent activation of IRF7 and suppressed IFN\u03b2 and IFN-I activated gene production. Int. J. Mol. Sci. 21, 8925 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1388_CR121","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ni1118","volume":"5","author":"T Kawai","year":"2004","unstructured":"Kawai, T. et al. Interferon-\u03b1 induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 5, 1061\u20131068 (2004).","journal-title":"Nat. Immunol."},{"key":"1388_CR122","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005674","volume":"4","author":"H Konno","year":"2009","unstructured":"Konno, H. et al. TRAF6 establishes innate immune responses by activating NF-\u03baB and IRF7 upon sensing cytosolic viral RNA and DNA. PLoS ONE 4, e5674 (2009).","journal-title":"PLoS ONE"},{"key":"1388_CR123","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.immuni.2014.08.011","volume":"41","author":"T Kobayashi","year":"2014","unstructured":"Kobayashi, T. et al. The histidine transporter SLC15A4 coordinates mTOR-dependent inflammatory responses and pathogenic antibody production. Immunity 41, 375\u2013388 (2014).","journal-title":"Immunity"},{"key":"1388_CR124","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2200544119","volume":"119","author":"I Rimann","year":"2022","unstructured":"Rimann, I. et al. The solute carrier SLC15A4 is required for optimal trafficking of nucleic acid-sensing TLRs and ligands to endolysosomes. Proc. Natl Acad. Sci. USA 119, e2200544119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1388_CR125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244439","volume":"16","author":"A Katewa","year":"2021","unstructured":"Katewa, A. et al. The peptide symporter SLC15a4 is essential for the development of systemic lupus erythematosus in murine models. PLoS ONE 16, e0244439 (2021).","journal-title":"PLoS ONE"},{"key":"1388_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10106-2","volume":"10","author":"CA Odhams","year":"2019","unstructured":"Odhams, C. A. et al. Interferon inducible X-linked gene CXorf21 may contribute to sexual dimorphism in systemic lupus erythematosus. Nat. Commun. 10, 2164 (2019).","journal-title":"Nat. Commun."},{"key":"1388_CR127","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/ng.3434","volume":"47","author":"J Bentham","year":"2015","unstructured":"Bentham, J. et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat. Genet. 47, 1457\u20131464 (2015).","journal-title":"Nat. Genet."},{"key":"1388_CR128","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/ng.472","volume":"41","author":"JW Han","year":"2009","unstructured":"Han, J. W. et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat. Genet. 41, 1234\u20131237 (2009).","journal-title":"Nat. Genet."},{"key":"1388_CR129","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1089\/gtmb.2015.0289","volume":"20","author":"M Zhang","year":"2016","unstructured":"Zhang, M., Chen, F., Zhang, D., Zhai, Z. & Hao, F. Association study between SLC15A4 polymorphisms and haplotypes and systemic lupus erythematosus in a Han Chinese population. Genet. Test. Mol. Biomarkers 20, 451\u2013458 (2016).","journal-title":"Genet. Test. Mol. Biomarkers"},{"key":"1388_CR130","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1002\/art.43243","volume":"77","author":"J Ma","year":"2025","unstructured":"Ma, J. et al. Trio whole exome sequencing in Chinese childhood-onset lupus reveals novel candidate genes. Arthritis Rheumatol. 77, 1548\u20131559\u00a0(2025).","journal-title":"Arthritis Rheumatol."},{"key":"1388_CR131","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nri1900","volume":"6","author":"K Honda","year":"2006","unstructured":"Honda, K. & Taniguchi, T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6, 644\u2013658 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"1388_CR132","doi-asserted-by":"publisher","first-page":"10154","DOI":"10.1073\/pnas.1005599107","volume":"107","author":"DA Savitsky","year":"2010","unstructured":"Savitsky, D. A., Yanai, H., Tamura, T., Taniguchi, T. & Honda, K. Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus. Proc. Natl Acad. Sci. USA 107, 10154\u201310159 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1388_CR133","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/ng.748","volume":"43","author":"TA Briggs","year":"2011","unstructured":"Briggs, T. A. et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat. Genet. 43, 127\u2013131 (2011).","journal-title":"Nat. Genet."},{"key":"1388_CR134","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jaci.2016.09.029","volume":"140","author":"A Hoshino","year":"2017","unstructured":"Hoshino, A. et al. Abnormal hematopoiesis and autoimmunity in human subjects with germline IKZF1 mutations. J. Allergy Clin. Immunol. 140, 223\u2013231 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1388_CR135","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jaci.2018.04.008","volume":"142","author":"E Van Nieuwenhove","year":"2018","unstructured":"Van Nieuwenhove, E. et al. A kindred with mutant IKAROS and autoimmunity. J. Allergy Clin. Immunol. 142, 699\u2013702.e12 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1388_CR136","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10875-019-00643-2","volume":"39","author":"Y Dieudonne","year":"2019","unstructured":"Dieudonne, Y., Guffroy, A., Vollmer, O., Carapito, R. & Korganow, A. S. IKZF1 Loss-of-function variant causes autoimmunity and severe familial antiphospholipid syndrome. J. Clin. Immunol. 39, 353\u2013357 (2019).","journal-title":"J. Clin. Immunol."},{"key":"1388_CR137","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s10875-019-00695-4","volume":"39","author":"R Duan","year":"2019","unstructured":"Duan, R. et al. A de novo frameshift mutation in TNFAIP3 impairs A20 deubiquitination function to cause neuropsychiatric systemic lupus erythematosus. J. Clin. Immunol. 39, 795\u2013804 (2019).","journal-title":"J. Clin. Immunol."},{"key":"1388_CR138","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/ckj\/sfac130","volume":"15","author":"C Zhang","year":"2022","unstructured":"Zhang, C. et al. Novel loss-of-function mutations in TNFAIP3 gene in patients with lupus nephritis. Clin. Kidney J. 15, 2027\u20132038 (2022).","journal-title":"Clin. Kidney J."},{"key":"1388_CR139","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.immuni.2010.07.017","volume":"33","author":"RM Tavares","year":"2010","unstructured":"Tavares, R. M. et al. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 33, 181\u2013191 (2010).","journal-title":"Immunity"},{"key":"1388_CR140","doi-asserted-by":"publisher","first-page":"214","DOI":"10.55563\/clinexprheumatol\/zte897","volume":"39","author":"G Li","year":"2021","unstructured":"Li, G. et al. Genetic heterogeneity in Chinese children with systemic lupus erythematosus. Clin. Exp. Rheumatol. 39, 214\u2013222 (2021).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1388_CR141","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/0021-9681(55)90018-7","volume":"1","author":"M Merrell","year":"1955","unstructured":"Merrell, M. & Shulman, L. E. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J. Chronic Dis. 1, 12\u201332 (1955).","journal-title":"J. Chronic Dis."},{"key":"1388_CR142","first-page":"1259","volume":"22","author":"M Abu-Shakra","year":"1995","unstructured":"Abu-Shakra, M., Urowitz, M. B., Gladman, D. D. & Gough, J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J. Rheumatol. 22, 1259\u20131264 (1995).","journal-title":"J. Rheumatol."},{"key":"1388_CR143","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/acr.22173","volume":"66","author":"M Yurkovich","year":"2014","unstructured":"Yurkovich, M., Vostretsova, K., Chen, W. & Avina-Zubieta, J. A. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res. 66, 608\u2013616 (2014).","journal-title":"Arthritis Care Res."},{"key":"1388_CR144","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/acr.24425","volume":"73","author":"S Bernatsky","year":"2021","unstructured":"Bernatsky, S. et al. Cancer risk in a large inception systemic lupus erythematosus cohort: effects of demographic characteristics, smoking, and medications. Arthritis Care Res. 73, 1789\u20131795 (2021).","journal-title":"Arthritis Care Res."},{"key":"1388_CR145","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.semarthrit.2017.01.010","volume":"47","author":"I Rua-Figueroa","year":"2017","unstructured":"Rua-Figueroa, I. et al. Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin. Arthritis Rheum. 47, 38\u201345 (2017).","journal-title":"Semin. Arthritis Rheum."},{"key":"1388_CR146","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1191\/096120399680411335","volume":"8","author":"DD Gladman","year":"1999","unstructured":"Gladman, D. D. & Urowitz, M. B. The SLICC\/ACR damage index: progress report and experience in the field. Lupus 8, 632\u2013637 (1999).","journal-title":"Lupus"},{"key":"1388_CR147","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/rheumatology\/kez516","volume":"59","author":"BT Segura","year":"2020","unstructured":"Segura, B. T. et al. Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. Rheumatology 59, 524\u2013533 (2020).","journal-title":"Rheumatology"},{"key":"1388_CR148","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/art.24341","volume":"61","author":"TY Lu","year":"2009","unstructured":"Lu, T. Y. et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 61, 482\u2013487 (2009).","journal-title":"Arthritis Rheum."},{"key":"1388_CR149","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222\u2013233 (2010).","journal-title":"Arthritis Rheum."},{"key":"1388_CR150","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab Study. Arthritis Rheum. 64, 1215\u20131226 (2012).","journal-title":"Arthritis Rheum."},{"key":"1388_CR151","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie, R. A. et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 81, 100\u2013107 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1388_CR152","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","volume":"392","author":"RA Furie","year":"2025","unstructured":"Furie, R. A. et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N. Engl. J. Med. 392, 1471\u20131483 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1388_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15083173","volume":"15","author":"M Xipell","year":"2026","unstructured":"Xipell, M. et al. Belimumab in systemic lupus erythematosus: from B-cell biology to disease modification. J. Clin. Med. 15, 3173 (2026).","journal-title":"J. Clin. Med."},{"key":"1388_CR154","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721\u2013731 (2011).","journal-title":"Lancet"},{"key":"1388_CR155","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie, R. et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918\u20133930 (2011).","journal-title":"Arthritis Rheum."},{"key":"1388_CR156","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie, R. et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N. Engl. J. Med. 383, 1117\u20131128 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1388_CR157","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1093\/rheumatology\/kep270","volume":"48","author":"M Aringer","year":"2009","unstructured":"Aringer, M. et al. Adverse events and efficacy of TNF-\u03b1 blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology 48, 1451\u20131454 (2009).","journal-title":"Rheumatology"},{"key":"1388_CR158","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1002\/art.24803","volume":"60","author":"JW Bauer","year":"2009","unstructured":"Bauer, J. W. et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 60, 3098\u20133107 (2009).","journal-title":"Arthritis Rheum."},{"key":"1388_CR159","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211\u2013221 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1388_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112238","volume":"193","author":"C Patinote","year":"2020","unstructured":"Patinote, C. et al. Agonist and antagonist ligands of toll-like receptors 7 and 8: ingenious tools for therapeutic purposes. Eur. J. Med. Chem. 193, 112238 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"1388_CR161","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1093\/nar\/gkt078","volume":"41","author":"ER Kandimalla","year":"2013","unstructured":"Kandimalla, E. R. et al. Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res. 41, 3947\u20133961 (2013).","journal-title":"Nucleic Acids Res."},{"key":"1388_CR162","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.clim.2016.09.015","volume":"174","author":"DM Balak","year":"2017","unstructured":"Balak, D. M. et al. IMO-8400, a Toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. Clin. Immunol. 174, 63\u201372 (2017).","journal-title":"Clin. Immunol."},{"key":"1388_CR163","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jaad.2020.07.122","volume":"84","author":"YJ Kim","year":"2021","unstructured":"Kim, Y. J. et al. A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7\/8\/9 antagonist, IMO-8400, in dermatomyositis. J. Am. Acad. Dermatol. 84, 1160\u20131162 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1388_CR164","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.1158\/0008-5472.CAN-17-3878","volume":"78","author":"F Calore","year":"2018","unstructured":"Calore, F. et al. The TLR7\/8\/9 antagonist IMO-8503 inhibits cancer-induced cachexia. Cancer Res. 78, 6680\u20136690 (2018).","journal-title":"Cancer Res."},{"key":"1388_CR165","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.4049\/jimmunol.174.9.5193","volume":"174","author":"O Duramad","year":"2005","unstructured":"Duramad, O. et al. Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J. Immunol. 174, 5193\u20135200 (2005).","journal-title":"J. Immunol."},{"key":"1388_CR166","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1084\/jem.20050914","volume":"202","author":"FJ Barrat","year":"2005","unstructured":"Barrat, F. J. et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202, 1131\u20131139 (2005).","journal-title":"J. Exp. Med."},{"key":"1388_CR167","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1600-065X.2008.00630.x","volume":"223","author":"FJ Barrat","year":"2008","unstructured":"Barrat, F. J. & Coffman, R. L. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol. Rev. 223, 271\u2013283 (2008).","journal-title":"Immunol. Rev."},{"key":"1388_CR168","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28020634","volume":"28","author":"H Zheng","year":"2023","unstructured":"Zheng, H., Wu, P. & Bonnet, P. A. Recent advances on small-molecule antagonists targeting TLR7. Molecules 28, 634 (2023).","journal-title":"Molecules"},{"key":"1388_CR169","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004701","volume":"10","author":"Y Tanaka","year":"2024","unstructured":"Tanaka, Y. et al. Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I\/II study in systemic lupus erythematosus. RMD Open. 10, e004701 (2024).","journal-title":"RMD Open."},{"key":"1388_CR170","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/intimm\/dxaf046","volume":"38","author":"R Fukui","year":"2026","unstructured":"Fukui, R. et al. Anti-human TLR7 antibody for therapeutic intervention in systemic lupus erythematosus. Int. Immunol. 38, 28\u201340 (2026).","journal-title":"Int. Immunol."},{"key":"1388_CR171","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7119","volume":"6","author":"A Kanno","year":"2015","unstructured":"Kanno, A. et al. Targeting cell surface TLR7 for therapeutic intervention in autoimmune diseases. Nat. Commun. 6, 6119 (2015).","journal-title":"Nat. Commun."},{"key":"1388_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(25)00337-6","author":"EF Morand","year":"2026","unstructured":"Morand, E. F. et al. Efficacy and safety of enpatoran, a Toll-like receptor 7\/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Rheumatol. https:\/\/doi.org\/10.1016\/S2665-9913(25)00337-6 (2026).","journal-title":"Lancet Rheumatol."},{"key":"1388_CR173","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/S0140-6736(26)00463-0","volume":"407","author":"EF Morand","year":"2026","unstructured":"Morand, E. F. et al. Enpatoran, a Toll-like receptor 7\/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial. Lancet 407, 1809\u20131824 (2026).","journal-title":"Lancet"},{"key":"1388_CR174","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.annder.2018.07.014","volume":"145","author":"AS Beltoise","year":"2018","unstructured":"Beltoise, A. S. et al. Familial chilblain lupus: four cases spanning three generations. Ann. Dermatol. Venereol. 145, 683\u2013689 (2018).","journal-title":"Ann. Dermatol. Venereol."},{"key":"1388_CR175","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"1388_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2025.168967","volume":"437","author":"J Fleming","year":"2025","unstructured":"Fleming, J. et al. AlphaFold protein structure database and 3d-beacons: new data and capabilities. J. Mol. Biol. 437, 168967 (2025).","journal-title":"J. Mol. Biol."}],"updated-by":[{"DOI":"10.1038\/s41584-026-01401-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000}}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01388-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01388-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01388-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:01:26Z","timestamp":1784894486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01388-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":176,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1388"],"URL":"https:\/\/doi.org\/10.1038\/s41584-026-01388-0","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"11 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41584-026-01401-6","URL":"https:\/\/doi.org\/10.1038\/s41584-026-01401-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.G.V. has received honoraria from Merck for speaking at scientific meetings and is a member of the Scientific Advisory Boards of Ensocell and Biogen. A.R. has received honorarium for speaking at a scientific meeting organized by GSK. M.S. declares no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}